Study to Evaluate the Efficacy and Safety of GSK239512 in Schizophrenia

Summary

This study aims to evaluate the cognitive enhancing effects and tolerability of GSK239512 compared to placebo in patients with schizophrenia

Timeline

Start

2009-12-01

Primary completion

2011-08-10

Completion

2011-08-10

Outcome

Missed primary endpoint

registry analysis (superiority or other test); Placebo vs GSK239512; p = 0.7239; Mean Difference (Net) -0.049 (90% CI -0.288 to 0.190); Mixed Model Repeated Measure NCT01009060 ↗

Publications

• Jarskog LF, Lowy MT, Grove RA, Keefe RS, Horrigan JP, Ball MP, Breier A, Buchanan RW, Carter CS, Csernansky JG, Goff DC, Green MF, Kantrowitz JT, Keshavan MS, Laurelle M, Lieberman JA, Marder SR, Maruff P, McMahon RP, Seidman LJ, Peykamian MA. A Phase II study of a histamine H(3) receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy. Schizophr Res. 2015 May;164(1-3):136-42. doi: 10.1016/j.schres.2015.01.041. Epub 2015 Feb 24.

Drugs

Indications